← 返回

抗吞噬阻断-抗复极化膜融合脂质体(ARMFUL)用于过继性细胞免疫治疗

英文原题:Anti-phagocytosis-blocking repolarization-resistant membrane-fusogenic liposome (ARMFUL) for adoptive cell immunotherapy.

查看英文原题

Anti-phagocytosis-blocking repolarization-resistant membrane-fusogenic liposome (ARMFUL) for adoptive cell immunotherapy.

PubMed 2023/08/09(内容时间) Sci Adv Q1 · IF 13.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

在过继效应细胞上装备多种功能对于克服实体瘤中复杂的免疫屏障以实现更优的抗肿瘤疗效至关重要。然而,当前的细胞工程技术无法在单一步骤中赋予细胞这些功能,因为靶标在单个细胞中的空间分布不同。在此,我们提出了一种核-壳型抗吞噬阻断-抗复极化膜融合脂质体(ARMFUL),以实现一步多重细胞工程用于多功能细胞构建。通过与M1巨噬细胞膜融合,ARMFUL将修饰有抗CD47(aCD47)的脂质壳插入细胞表面,同时将负载集落刺激因子1受体抑制剂BLZ945的核递送至细胞质中。表面呈递的aCD47通过阻断CD47增强巨噬细胞对肿瘤的吞噬作用。位于细胞质中的BLZ945通过灭活细胞内M2极化信号通路,促使其在免疫抑制微环境中抵抗向M2表型极化。该ARMFUL提供了一种多功能的细胞工程平台,可定制多模式细胞功能以增强过继细胞治疗。

展开英文摘要原文

Equipping multiple functionalities on adoptive effector cells is essential to overcome the complex immunological barriers in solid tumors for superior antitumor efficacy.

However, current cell engineering technologies cannot endow these functionalities to cells within a single step because of the different spatial distributions of targets in one cell.

Here, we present a core-shell anti-phagocytosis-blocking repolarization-resistant membrane-fusogenic liposome (ARMFUL) to achieve one-step multiplexing cell engineering for multifunctional cell construction. Through fusing with the M1 macrophage membrane, ARMFUL inserts an anti-CD47 (aCD47)-modified lipid shell onto the surface and simultaneously delivers colony-stimulating factor 1 receptor inhibitor BLZ945-loaded core into the cytoplasm.

The surface-presenting aCD47 boosts macrophage's phagocytosis against the tumor by blocking CD47. The cytoplasm-located BLZ945 prompts its polarization resistance to M2 phenotype in the immunosuppressive microenvironment via inactivating the intracellular M2 polarization signaling pathway. This ARMFUL provides a versatile cell engineering platform to customize multimodal cellular functions for enhanced adoptive cell therapy.

论文信息

作者
Zheng C、Zhong Q、Yi K、Kong H、Cao F、Zhuo C、Xu Y、Shi R
单位
Laboratory of Biomaterials and Translational Medicine, Center for Nanomedicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China.China
期刊
Science advances2023 Aug 9
原文标识
PubMed 37556535 · DOI 10.1126/sciadv.adh2413